膿毒癥相關性急性呼吸窘迫綜合征生物標志物研究進展_Chinese Journal of Respiratory and Critical Care Medicine

Authors：

孫媛 ¹ , 王琳 ¹ ,  李筱妍 ²

1. ;
2. ;

Corresponding?author：

李筱妍, Email: 2415960869@qq.com

Keywords：

DOI：

10.7507/1671-6205.202305027

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 孫媛, 王琳, 李筱妍. 膿毒癥相關性急性呼吸窘迫綜合征生物標志物研究進展. Chinese Journal of Respiratory and Critical Care Medicine, 2023, 22(10): 745-748. doi: 10.7507/1671-6205.202305027 Copy

1.	Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA, 2016, 315(8): 801-810.
2.	Meyer NJ, Gattinoni L, Calfee CS. Acute respiratory distress syndrome. Lancet, 2021, 398(10300): 622-637.
3.	Basodan N, Al Mehmadi AE, Al Mehmadi AE, et al. Septic shock: management and outcomes. Cureus, 2022, 14(12): e32158.
4.	Gong HK, Chen Y, Chen ML, et al. Advanced development and mechanism of sepsis-related acute respiratory distress syndrome. Front Med (Lausanne), 2022, 9: 1043859.
5.	Maruna P, Nedelníková K, Gürlich R. Physiology and genetics of procalcitonin. Physiol Res, 2000, 49 Suppl 1: S57-S61.
6.	Plata-Menchaca EP, Ferrer R. Procalcitonin is useful for antibiotic deescalation in sepsis. Crit Care Med, 2021, 49(4): 693-696.
7.	Rezaeinasab M, Rad M. Analytical survey of human rabies and animal bite prevalence during one decade in the province of Kerman, Iran. Crit Care, 2008, 12(Suppl 2): P1.
8.	Tsantes A, Tsangaris I, Kopterides P, et al. The role of procalcitonin and IL-6 in discriminating between septic and non-septic causes of ALI/ARDS: a prospective observational study. Clin Chem Lab Med, 2013, 51(7): 1535-1542.
9.	Akwii RG, Sajib MS, Zahra FT, et al. Role of angiopoietin-2 in vascular physiology and pathophysiology. Cells, 2019, 8(5): 471.
10.	Parikh SM. The angiopoietin-Tie2 signaling axis in systemic inflammation. J Am Soc Nephrol, 2017, 28(7): 1973-1982.
11.	Saharinen P, Lepp?nen VM, Alitalo K. SnapShot: angiopoietins and their functions. Cell, 2017 171(3): 724. e1.
12.	Bhandari V, Choo-Wing R, Lee CG, et al. Hyperoxia causes angiopoietin 2-mediated acute lung injury and necrotic cell death. Nat Med, 2006, 12(11): 1286-1293.
13.	Tsangaris I, Tsantes A, Vrigkou E, et al. Angiopoietin-2 levels as predictors of outcome in mechanically ventilated patients with acute respiratory distress syndrome. Dis Markers, 2017, 2017: 6758721.
14.	Gutbier B, Neuhauss AK, Reppe K, et al. Prognostic and pathogenic role of angiopoietin-1 and -2 in pneumonia. Am J Respir Crit Care Med, 2018, 198(2): 220-231.
15.	Reilly JP, Wang F, Jones TK, et al. Plasma angiopoietin-2 as a potential causal marker in sepsis-associated ARDS development: evidence from Mendelian randomization and mediation analysis. Intensive Care Med, 2018, 44(11): 1849-1858.
16.	Rajput C, Tauseef M, Farazuddin M, et al. MicroRNA-150 suppression of angiopoetin-2 generation and signaling is crucial for resolving vascular injury. Arterioscler Thromb Vasc Biol, 2016, 36(2): 380-388.
17.	Han S, Lee SJ, Kim KE, et al. Amelioration of sepsis by TIE2 activation-induced vascular protection. Sci Transl Med, 2016, 8(335): 335ra55.
18.	Mostafa S, Pakvasa M, Coalson E, et al. The wonders of BMP9: from mesenchymal stem cell differentiation, angiogenesis, neurogenesis, tumorigenesis, and metabolism to regenerative medicine. Genes Dis, 2019, 6(3): 201-223.
19.	Liu W, Deng ZL, Zeng ZY, et al. Highly expressed BMP9/GDF2 in postnatal mouse liver and lungs may account for its pleiotropic effects on stem cell differentiation, angiogenesis, tumor growth and metabolism. Genes Dis, 2020, 7(2): 235-244.
20.	Song TZ, Huang DM, Song DZ. The potential regulatory role of BMP9 in inflammatory responses. Genes Dis, 2022, 9(6): 1566-1578.
21.	Chen XY, Orriols M, Walther FJ, et al. Bone morphogenetic protein 9 protects against neonatal hyperoxia-induced impairment of alveolarization and pulmonary inflammation. Front Physiol, 2017, 8: 486.
22.	Li W, Long L, Yang XD, et al. Circulating BMP9 protects the pulmonary endothelium during inflammation-induced lung injury in mice. Am J Respir Crit Care Med, 2021, 203(11): 1419-1430.
23.	Flippo KH, Potthoff MJ. Metabolic messengers: FGF21. Nat Metab, 2021, 3(3): 309-317.
24.	Yao D, He QL, Sun JW, et al. FGF21 attenuates hypoxia-induced dysfunction and inflammation in HPAECs via the microRNA-27b-mediated PPARγ pathway. Int J Mol Med, 2021 47(6): 116.
25.	Gao J, Liu QH, Li JL, et al. Fibroblast growth factor 21 dependent TLR4/MYD88/NF-κB signaling activation is involved in lipopolysaccharide-induced acute lung injury. Int Immunopharmacol, 2020, 80: 106219.
26.	Li X, Zhu ZX, Zhou TH, et al. Predictive value of combined serum FGF21 and free T3 for survival in septic patients. Clin Chim Acta, 2019, 494: 31-37.
27.	Li X, Shen H, Zhou TH, et al. Does an increase in serum FGF21 level predict 28-day mortality of critical patients with sepsis and ARDS? Respir Res, 2021, 22(1): 182.
28.	Yan F, Yuan L, Yang F, et al. Emerging roles of fibroblast growth factor 21 in critical disease. Front Cardiovasc Med, 2022, 9: 1053997.
29.	Galliera E, Massaccesi L, de Vecchi E, et al. Clinical application of presepsin as diagnostic biomarker of infection: overview and updates. Clin Chem Lab Med, 2019, 58(1): 11-17.
30.	Park JE, Lee B, Yoon SJ, et al. Complementary use of presepsin with the Sepsis-3 Criteria improved identification of high-risk patients with suspected sepsis. Biomedicines, 2021, 9(9): 1076.
31.	Ali FT, Ali MA, Elnakeeb MM, et al. Presepsin is an early monitoring biomarker for predicting clinical outcome in patients with sepsis. Clin Chim Acta, 2016, 460: 93-101.
32.	Assal HH, Abdelrahman SM, Abdelbasset MA, et al. Presepsin as a novel biomarker in predicting in-hospital mortality in patients with COVID-19 pneumonia. Int J Infect Dis, 2022, 118: 155-163.
33.	El Gendy FM, El-Mekkawy MS, Saleh N , et al. Clinical study of presepsin and pentraxin 3 in critically ill children. J Crit Care, 2018, 47: 36-40.
34.	Zhao JN, Tan Y, Wang L, et al. Discriminatory ability and prognostic evaluation of presepsin for sepsis-related acute respiratory distress syndrome. Sci Rep, 2020, 10(1): 9114.
35.	Yang M, Wei WB. SNHG16: a novel long-non coding RNA in human cancers. Onco Targets Ther, 2019, 12: 11679-11690.
36.	Xia L, Zhu GQ, Huang HY, et al. LncRNA small nucleolar RNA host gene 16 (SNHG16) silencing protects lipopolysaccharide (LPS)-induced cell injury in human lung fibroblasts WI-38 through acting as miR-141-3p sponge. Biosci Biotechnol Biochem, 2021, 85(5): 1077-1087.
37.	Wang WY, Lou CY, Gao J, et al. LncRNA SNHG16 reverses the effects of miR-15a/16 on LPS-induced inflammatory pathway. Biomed Pharmacother, 2018, 106: 1661-1667.
38.	Gao PJ, Wang J, Jiang M, et al. LncRNA SNHG16 is downregulated in pneumonia and downregulates miR-210 to promote LPS-induced lung cell apoptosis. Mol Biotechnol, 2023, 65(3): 446-452.
39.	Zhang CJ, Huang QH, He FY. Correlation of small nucleolar RNA host gene 16 with acute respiratory distress syndrome occurrence and prognosis in sepsis patients. J Clin Lab Anal, 2022, 36(7): e24516.
40.	Miao H, Chen S, Ding RY. Evaluation of the molecular mechanisms of sepsis using proteomics. Front Immunol, 2021, 12: 733537.
41.	Shu T, Ning WS, Wu D, et al. Plasma proteomics identify biomarkers and pathogenesis of COVID-19. Immunity, 2020, 53(5): 1108-1122. e1105.
42.	Wang CL, Li Y, Li SL, et al. Proteomics combined with RNA sequencing to screen biomarkers of sepsis. Infect Drug Resist, 2022, 15: 5575-5587.
43.	Yehya N, Fazelinia H, Taylor DM, et al. Differentiating children with sepsis with and without acute respiratory distress syndrome using proteomics. Am J Physiol Lung Cell Mol Physiol, 2022, 322(3): L365-L372.

1. Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA, 2016, 315(8): 801-810.
2. Meyer NJ, Gattinoni L, Calfee CS. Acute respiratory distress syndrome. Lancet, 2021, 398(10300): 622-637.
3. Basodan N, Al Mehmadi AE, Al Mehmadi AE, et al. Septic shock: management and outcomes. Cureus, 2022, 14(12): e32158.
4. Gong HK, Chen Y, Chen ML, et al. Advanced development and mechanism of sepsis-related acute respiratory distress syndrome. Front Med (Lausanne), 2022, 9: 1043859.
5. Maruna P, Nedelníková K, Gürlich R. Physiology and genetics of procalcitonin. Physiol Res, 2000, 49 Suppl 1: S57-S61.
6. Plata-Menchaca EP, Ferrer R. Procalcitonin is useful for antibiotic deescalation in sepsis. Crit Care Med, 2021, 49(4): 693-696.
7. Rezaeinasab M, Rad M. Analytical survey of human rabies and animal bite prevalence during one decade in the province of Kerman, Iran. Crit Care, 2008, 12(Suppl 2): P1.
8. Tsantes A, Tsangaris I, Kopterides P, et al. The role of procalcitonin and IL-6 in discriminating between septic and non-septic causes of ALI/ARDS: a prospective observational study. Clin Chem Lab Med, 2013, 51(7): 1535-1542.
9. Akwii RG, Sajib MS, Zahra FT, et al. Role of angiopoietin-2 in vascular physiology and pathophysiology. Cells, 2019, 8(5): 471.
10. Parikh SM. The angiopoietin-Tie2 signaling axis in systemic inflammation. J Am Soc Nephrol, 2017, 28(7): 1973-1982.
11. Saharinen P, Lepp?nen VM, Alitalo K. SnapShot: angiopoietins and their functions. Cell, 2017 171(3): 724. e1.
12. Bhandari V, Choo-Wing R, Lee CG, et al. Hyperoxia causes angiopoietin 2-mediated acute lung injury and necrotic cell death. Nat Med, 2006, 12(11): 1286-1293.
13. Tsangaris I, Tsantes A, Vrigkou E, et al. Angiopoietin-2 levels as predictors of outcome in mechanically ventilated patients with acute respiratory distress syndrome. Dis Markers, 2017, 2017: 6758721.
14. Gutbier B, Neuhauss AK, Reppe K, et al. Prognostic and pathogenic role of angiopoietin-1 and -2 in pneumonia. Am J Respir Crit Care Med, 2018, 198(2): 220-231.
15. Reilly JP, Wang F, Jones TK, et al. Plasma angiopoietin-2 as a potential causal marker in sepsis-associated ARDS development: evidence from Mendelian randomization and mediation analysis. Intensive Care Med, 2018, 44(11): 1849-1858.
16. Rajput C, Tauseef M, Farazuddin M, et al. MicroRNA-150 suppression of angiopoetin-2 generation and signaling is crucial for resolving vascular injury. Arterioscler Thromb Vasc Biol, 2016, 36(2): 380-388.
17. Han S, Lee SJ, Kim KE, et al. Amelioration of sepsis by TIE2 activation-induced vascular protection. Sci Transl Med, 2016, 8(335): 335ra55.
18. Mostafa S, Pakvasa M, Coalson E, et al. The wonders of BMP9: from mesenchymal stem cell differentiation, angiogenesis, neurogenesis, tumorigenesis, and metabolism to regenerative medicine. Genes Dis, 2019, 6(3): 201-223.
19. Liu W, Deng ZL, Zeng ZY, et al. Highly expressed BMP9/GDF2 in postnatal mouse liver and lungs may account for its pleiotropic effects on stem cell differentiation, angiogenesis, tumor growth and metabolism. Genes Dis, 2020, 7(2): 235-244.
20. Song TZ, Huang DM, Song DZ. The potential regulatory role of BMP9 in inflammatory responses. Genes Dis, 2022, 9(6): 1566-1578.
21. Chen XY, Orriols M, Walther FJ, et al. Bone morphogenetic protein 9 protects against neonatal hyperoxia-induced impairment of alveolarization and pulmonary inflammation. Front Physiol, 2017, 8: 486.
22. Li W, Long L, Yang XD, et al. Circulating BMP9 protects the pulmonary endothelium during inflammation-induced lung injury in mice. Am J Respir Crit Care Med, 2021, 203(11): 1419-1430.
23. Flippo KH, Potthoff MJ. Metabolic messengers: FGF21. Nat Metab, 2021, 3(3): 309-317.
24. Yao D, He QL, Sun JW, et al. FGF21 attenuates hypoxia-induced dysfunction and inflammation in HPAECs via the microRNA-27b-mediated PPARγ pathway. Int J Mol Med, 2021 47(6): 116.
25. Gao J, Liu QH, Li JL, et al. Fibroblast growth factor 21 dependent TLR4/MYD88/NF-κB signaling activation is involved in lipopolysaccharide-induced acute lung injury. Int Immunopharmacol, 2020, 80: 106219.
26. Li X, Zhu ZX, Zhou TH, et al. Predictive value of combined serum FGF21 and free T3 for survival in septic patients. Clin Chim Acta, 2019, 494: 31-37.
27. Li X, Shen H, Zhou TH, et al. Does an increase in serum FGF21 level predict 28-day mortality of critical patients with sepsis and ARDS? Respir Res, 2021, 22(1): 182.
28. Yan F, Yuan L, Yang F, et al. Emerging roles of fibroblast growth factor 21 in critical disease. Front Cardiovasc Med, 2022, 9: 1053997.
29. Galliera E, Massaccesi L, de Vecchi E, et al. Clinical application of presepsin as diagnostic biomarker of infection: overview and updates. Clin Chem Lab Med, 2019, 58(1): 11-17.
30. Park JE, Lee B, Yoon SJ, et al. Complementary use of presepsin with the Sepsis-3 Criteria improved identification of high-risk patients with suspected sepsis. Biomedicines, 2021, 9(9): 1076.
31. Ali FT, Ali MA, Elnakeeb MM, et al. Presepsin is an early monitoring biomarker for predicting clinical outcome in patients with sepsis. Clin Chim Acta, 2016, 460: 93-101.
32. Assal HH, Abdelrahman SM, Abdelbasset MA, et al. Presepsin as a novel biomarker in predicting in-hospital mortality in patients with COVID-19 pneumonia. Int J Infect Dis, 2022, 118: 155-163.
33. El Gendy FM, El-Mekkawy MS, Saleh N , et al. Clinical study of presepsin and pentraxin 3 in critically ill children. J Crit Care, 2018, 47: 36-40.
34. Zhao JN, Tan Y, Wang L, et al. Discriminatory ability and prognostic evaluation of presepsin for sepsis-related acute respiratory distress syndrome. Sci Rep, 2020, 10(1): 9114.
35. Yang M, Wei WB. SNHG16: a novel long-non coding RNA in human cancers. Onco Targets Ther, 2019, 12: 11679-11690.
36. Xia L, Zhu GQ, Huang HY, et al. LncRNA small nucleolar RNA host gene 16 (SNHG16) silencing protects lipopolysaccharide (LPS)-induced cell injury in human lung fibroblasts WI-38 through acting as miR-141-3p sponge. Biosci Biotechnol Biochem, 2021, 85(5): 1077-1087.
37. Wang WY, Lou CY, Gao J, et al. LncRNA SNHG16 reverses the effects of miR-15a/16 on LPS-induced inflammatory pathway. Biomed Pharmacother, 2018, 106: 1661-1667.
38. Gao PJ, Wang J, Jiang M, et al. LncRNA SNHG16 is downregulated in pneumonia and downregulates miR-210 to promote LPS-induced lung cell apoptosis. Mol Biotechnol, 2023, 65(3): 446-452.
39. Zhang CJ, Huang QH, He FY. Correlation of small nucleolar RNA host gene 16 with acute respiratory distress syndrome occurrence and prognosis in sepsis patients. J Clin Lab Anal, 2022, 36(7): e24516.
40. Miao H, Chen S, Ding RY. Evaluation of the molecular mechanisms of sepsis using proteomics. Front Immunol, 2021, 12: 733537.
41. Shu T, Ning WS, Wu D, et al. Plasma proteomics identify biomarkers and pathogenesis of COVID-19. Immunity, 2020, 53(5): 1108-1122. e1105.
42. Wang CL, Li Y, Li SL, et al. Proteomics combined with RNA sequencing to screen biomarkers of sepsis. Infect Drug Resist, 2022, 15: 5575-5587.
43. Yehya N, Fazelinia H, Taylor DM, et al. Differentiating children with sepsis with and without acute respiratory distress syndrome using proteomics. Am J Physiol Lung Cell Mol Physiol, 2022, 322(3): L365-L372.

Previous Article
原發性肺外周T細胞淋巴瘤一例并文獻復習
Next Article
肺纖維化合并肺氣腫定義為“綜合征”的研究進展

Chinese Journal of Respiratory and Critical Care Medicine

膿毒癥相關性急性呼吸窘迫綜合征生物標志物研究進展

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content